FDA approved adjunctive therapy for partial-onset seizures¹

• Third-generation antiepileptic drug that selectively enhances the slow inactivation of voltage-gated sodium channels²
• Possess favourable pharmacokinetic profile with low protein binding and low potential for drug-drug interactions3
• Can be considered as an alternative to Fosphenytoin in the treatment of nonconvulsive seizures (NCS)⁴
• Offers good tolerability and safety for use in status epilepticus (SE)⁵

FDA approved adjunctive therapy for partial-onset seizures¹

• Third-generation antiepileptic drug that selectively enhances the slow inactivation of voltage-gated sodium channels²
• Possess favourable pharmacokinetic profile with low protein binding and low potential for drug-drug interactions3
• Can be considered as an alternative to Fosphenytoin in the treatment of nonconvulsive seizures (NCS)⁴
• Offers good tolerability and safety for use in status epilepticus (SE)⁵